Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802

被引：0
|
作者：
Asano, M. [1 ]
Tanaka, S. [1 ]
Sato, A. [1 ]
Nakayama, N. [1 ]
Shimada, K. [1 ]
Konishi, K. [1 ]
Hibi, K. [1 ]
Sasaki, E. [1 ]
Kurihara, M. [1 ]
机构：
[1] Tokyo Cooperat Oncol Grp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
578
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study
    Nakayama, Norisuke
    Sato, Atsushi
    Tanaka, Soichi
    Shimada, Ken
    Konishi, Kazuo
    Sasaki, Eisaku
    Hibi, Kenji
    Ichikawa, Hiroko
    Kikuchi, Yoshinori
    Sakuyama, Toshikazu
    Sekikawa, Takashi
    Hayashi, Kazuhiko
    Nishina, Haruhiro
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 954 - 962
  • [2] A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study
    Norisuke Nakayama
    Atsushi Sato
    Soichi Tanaka
    Ken Shimada
    Kazuo Konishi
    Eisaku Sasaki
    Kenji Hibi
    Hiroko Ichikawa
    Yoshinori Kikuchi
    Toshikazu Sakuyama
    Takashi Sekikawa
    Kazuhiko Hayashi
    Haruhiro Nishina
    Investigational New Drugs, 2015, 33 : 954 - 962
  • [3] First-line panitumumab combined with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): data from a phase II, single-arm, multicentre study (20060314)
    Karthaus, M.
    Greil, R.
    Mineur, L.
    Letocha, H.
    Thaler, J.
    Hofheinz, R.
    Fernebro, E.
    Gamelin, E.
    DeCosta, L.
    Koehne, C.-H.
    ONKOLOGIE, 2010, 33 : 62 - 62
  • [4] PRIMARY ANALYSIS OF A PHASE II, SINGLE-ARM STUDY (20060314) COMBINING PANITUMUMAB WITH FOLFIRI IN THE FIRST LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Koehne, C. H.
    Mineur, L.
    Greil, R.
    Letocha, H.
    Thaler, J.
    Hofheinz, R.
    Fernebro, E.
    Gamelin, E.
    Wright, L.
    Karthaus, M.
    ANNALS OF ONCOLOGY, 2010, 21 : I51 - I51
  • [5] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lima, C. S. Rocha
    Baranda, J. C.
    Wallmark, J.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [6] A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
    Kim, Youjin
    Kim, Tae Won
    Han, Sae Won
    Ahn, Joong Bae
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 1128 - 1134
  • [7] Interim analysis of epidermal-growth factor receptor (EGFR) expression in a single-arm, phase II, first-line study (20060314) of panitumumab with FOLFIRI in the management of metastatic colorectal cancer (mCRC)
    Koehne, C.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Gamelin, E.
    Fernebro, E.
    Wright, L.
    Karthaus, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 343 - 344
  • [8] Effectiveness and Safety of Bevacizumab(BV) plus FOLFIRI as First-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study
    Fourrier-Reglat, A.
    Rouyer, M.
    Benichou, J.
    Balestra, A.
    Bernard, M. A.
    Grelaud, A.
    Smith, D.
    Ravaud, A.
    Moore, N.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S28 - S28
  • [9] KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Salvatore, L.
    Loupakis, F.
    Fontanini, G.
    Cremolini, C.
    Stasi, I.
    Fabbri, A.
    Ciarlo, A.
    Granetto, C.
    Basolo, F.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [10] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
12345